P184 Once-daily versus twice-daily mesalazine for mild to moderately active ulcerative colitis: Mucosal healing and early response data from MOTUS, a multicentre, controlled, randomised, investigator-blinded study
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.